India Pharma Outlook Team | Monday, 23 May 2022
Akums Drugs & Pharmaceuticals Ltd acquired the license to manufacture and commercialise Bempedoic acid tablet, the drug which is used for treating high LDL-cholesterol conditions that’s indicative of cardiovascular diseases.
The pharma firm informed that Bempedoic acid drug is known to be low risk for patients with intolerability for statins, an important ingredient in most lipid-lowering drugs, it’s really beneficial to the Indian population that has a high incidence of LDL and heart diseases. “Akums drugs will soon begin manufacturing this novel, first-in-India, lipid-lowering drug, which could be a boon to the several Indians living with heart conditions. As per statistics, there’re 112 million Indian adults suffer from high levels of LDL-cholesterol, out of this significantly high number of dyslipidaemic patients, who are already on statin-based treatments still continue to suffer from uncontrolled dyslipidaemia—for such patients, Bempedoic acid will be a boon.
Our research and development teams are working on various combinations of Bempedoic plus other molecules and soon these innovative products will also be introduced in India," said Sandeep Jain,Founder, Promoter and Director, Akums Drugs & Pharmaceuticals. Informing that Bempedoic acid has shown positive results in supporting therapy in patients unable to tolerate or unresponsive to statins, Sanjeev Jain, Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, said, “This therapy is
an important addition to the management of dyslipidaemia through effective disease management. We are glad to be a part of such path-breaking initiatives and hope that together with our customers in pharmaceuticals, we will capture significant market share and be the pioneers in introducing the complete range of Bempedoic acid.” New Delhi : Akums Drugs & Pharmaceuticals Ltd acquired the license to manufacture and commercialise Bempedoic acid tablet, the drug which is used for treating high LDL-cholesterol conditions that’s indicative of cardiovascular diseases.
The pharma firm informed that Bempedoic acid drug is known to be low risk for patients with intolerability for statins, an important ingredient in most lipid-lowering drugs, it’s really beneficial to the Indian population that has a high incidence of LDL and heart diseases.
“Akums drugs will soon begin manufacturing this novel, first-in-India, lipid-lowering drug, which could be a boon to the several Indians living with heart conditions.
As per statistics, there’re 112 million Indian adults suffer from high levels of LDL-cholesterol, out of this significantly high number of dyslipidaemic patients, who are already on statin-based treatments still continue to suffer from uncontrolled dyslipidaemia—for such patients, Bempedoic acid will be a boon. Our research and development teams are working on various combinations of Bempedoic plus other molecules and soon these innovative products will also be introduced in India," said Sandeep Jain,Founder, Promoter and Director, Akums Drugs & Pharmaceuticals.
Informing that Bempedoic acid has shown positive results in supporting therapy in patients unable to tolerate or unresponsive to statins, Sanjeev Jain, Founder, Promoter and Director, Akums Drugs & Pharmaceuticals, said, “This therapy is an important addition to the management of dyslipidaemia through effective disease management. We are glad to be a part of such path-breaking initiatives and hope that together with our customers in pharmaceuticals, we will capture significant market share and be the pioneers in introducing the complete range of Bempedoic acid.”
, CDSCO.jpg)
